ArticleFrontiers in oncology2026
The survival impact of upfront or sequential chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The treatment of locally advanced unresectable esophageal squamous cell carcinoma (ESCC) is a clinical challenge with limited therapeutic consensus. The immune checkpoint inhibitor (ICI)-based conversion therapies emerged as an option besides definitive chemoradiotherapy (DCRT). Especially for those returned to DCRT after unsuccessful conversion therapy (salvage), the clinical outcome remained overlooked when compared with upfront DCRT. Methods: This study retrospectively analyzed the clinical data of patients with locally advanced ESCC who had received DCRT either as upfront or salvage therapy from 2018 to 2024. Overall survival (OS), event-free survival (EFS), progression-free survival (PFS) and objective remission rate (ORR) were assessed. Results: Totally 848 patients from 3 medical centers were screened, and 91 patients were included. The overall objective remission rate (ORR) was achieved in 28 cases (68.29%) in the salvage group, higher than the upfront group (26.00%, P < 0.001). Following conversion therapy, 11 patients achieved an ORR of 26.83%. After completing salvage DCRT, CR was observed in 2 patients (4.88%) and PR in 26 patients (63.41%). PFS was 20.3 months (95% CI: 11.6-28.9 months) and 6.4 months in the salvage and upfront group (HR 0.36, 95%CI: 0.19-0.66; P = 0.001). The median OS for the entire cohort was 24.6 months (95% CI 19.5-29.8 months), with a median OS of 42.2 months in the salvage group compared with 15.9 months in the upfront group (HR 0.39, 95% CI: 0.22-0.69; P = 0.001). The salvage group showed significantly longer OS than the upfront group, with 1-year OS rates of 95.1% and 56.9%, and 2-year OS rates of 68.8% and 36.6%, respectively. Conclusion: The salvage DCRT significantly improved the survival outcomes of patients with locally advanced unresectable ESCC over upfront DCRT. These findings support the clinical feasibility of this strategy and underscore the need for prospective randomized trials to validate its role as a new treatment paradigm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.